Daiichi Sankyo ... The DXd ADC portfolio currently consists of Enhertu, a HER2 directed ADC, and Datroway, a TROP2 directed ADC, which are being jointly developed and commercialized globally with ...

Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo's TROP2-targeting ... advanced non-squamous NSCLC. The HER3-directed ADC will be tested in patients whose ...

is a HER3-targeted ADC in late-stage clinical testing for lung cancer. Together, the three ADCs are billed as one of the strategic pillars of Daiichi Sankyo's current five-year business plan to 2025.

This was a significant finding compared to the 71.8% growth inhibition with the experimental HER3-targeting ADC, patritumab deruxtecan, which is currently being developed by Merck (NSE:PROR) and ...

The global ADC drug market is expected to reach $575 billion in 2033, but companies such as Pfizer and Daiichi Sankyo have already deployed similar targets. Direct competitors of BL-B01D1 include ...

Daiichi Sankyo ... III trial to evaluate the ADC in HER2-positive advanced gastric cancer, and its safety profile remains consistent with previous findings. Daiichi Sankyo R&D global head Ken ...

Daiichi Sankyo is stepping up its interest in RNA therapies, teaming with Nosis Biosciences to design drug candidates capable of reaching targets beyond the liver. The Japanese drugmaker is best ...

AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a randomized clinical trial in second-line metastatic stomach cancer ...

As AstraZeneca awaits an FDA decision for its Daiichi Sankyo-partnered Datroway in EGFR-mutated non-small cell lung cancer ...